GlassScriptPhysician profile
Bruno R Bastos
NPI 1619178936
$105,704.22
in general payments reported to CMS, 2019-2025
61 companies · $7,315 in 2025
The $7,315 reported for 2025 was more than what 86% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $18K · 2021: $32K · 2022: $15K · 2023: $2,520 · 2024: $11K · 2025: $7,315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $7,825 · Travel and Lodging: $803 · Education: $469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,055.00 |
| Food and Beverage | $7,824.66 |
| Travel and Lodging | $802.93 |
| Education | $469.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $21,117.44 | 2020-2025 | |
| Genzyme Corporation | $18,209.15 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $16,538.06 | 2019-2025 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $8,356.89 | 2019-2025 | |
| Eli Lilly and Company | $8,350.00 | 2021-2023 | |
| Exelixis INC. | $6,040.39 | 2021-2025 | Cabometyx |
| Astrazeneca Pharmaceuticals LP | $4,368.55 | 2019-2025 | Tagrisso, Imfinzi, Enhertu |
| Janssen Biotech, INC. | $3,015.99 | 2021-2025 | Erleada, Darzalex, Carvykti |
| Gilead Sciences, INC. | $2,688.41 | 2022-2025 | Trodelvy |
| Myovant Sciences INC. | $2,560.00 | 2022 | |
| Astellas Pharma Global Development | $2,102.07 | 2024 | Padcev |
| Dendreon Pharmaceuticals LLC | $1,645.72 | 2019-2025 | Provenge |
| Aveo Pharmaceuticals, INC. | $1,588.79 | 2021-2025 | |
| Astellas Pharma US INC | $1,279.05 | 2020-2025 | Xtandi, Padcev |
| Epizyme, INC. | $1,268.99 | 2021 |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $836.30 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $817.50 | 2024 | |
| Abbvie INC. | $551.52 | 2024-2025 | |
| Celgene Corporation | $484.51 | 2024-2025 | Reblozyl, Breyanzi |
| Daiichi Sankyo INC. | $416.69 | 2024-2025 | Enhertu, Datroway, Injectafer |
| Novartis Pharmaceuticals Corporation | $386.30 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $281.96 | 2020-2025 | Keytruda, Keytruda Qlex, Welireg |
| Eisai INC. | $279.22 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $251.16 | 2020-2025 | Iclusig, Ninlaro |
| Incyte Corporation | $148.14 | 2024-2025 | Jakafi, Monjuvi, Pemazyre |
| Tempus Ai, INC | $139.34 | 2025 | Xt Cdx |
| E.R. Squibb & Sons, L.L.C. | $130.96 | 2024-2025 | Opdivo |
| Sumitomo Pharma America, INC. | $104.21 | 2024-2025 | Orgovyx |
| Lilly USA, LLC | $98.51 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Deciphera Pharmaceuticals INC. | $94.57 | 2025 | Qinlock, Romvimza, Tgct |
| Intuitive Surgical, INC. | $93.69 | 2025 | |
| Springworks Therapeutics, INC. | $90.42 | 2024-2025 | Ogsiveo |
| Beone Medicines USA, INC. | $86.14 | 2025 | Tevimbra |
| Taiho Oncology, INC. | $85.53 | 2024-2025 | |
| Array Biopharma INC | $84.39 | 2024-2025 | Mektovi, Xalkori, Lorbrena |
| Stemline Therapeutics INC. | $83.86 | 2025 | Orserdu |
| Adaptive Biotechnologies Corporation | $76.60 | 2024-2025 | Clonoseq |
| Rigel Pharmaceuticals, INC. | $73.33 | 2025 | Gavreto, Tavalisse, Rezlidhia |
| Servier Pharmaceuticals LLC | $73.05 | 2024-2025 | |
| Beigene USA, INC. | $72.41 | 2024-2025 | Tevimbra, Brukinsa |
| Pharmacosmos Therapeutics INC. | $67.84 | 2025 | Monoferric |
| Sobi, INC | $66.64 | 2024-2025 | |
| Genentech USA, INC. | $61.59 | 2024-2025 | Polivy, Venclexta, Itovebi |
| Ipsen Biopharmaceuticals, INC | $54.64 | 2025 | Onivyde |
| Legend Biotech USA INC. | $54.06 | 2025 | Carvykti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.30 | 2024-2025 | Gilotrif |
| Syndax Pharmaceuticals, INC. | $46.49 | 2025 | |
| Jazz Pharmaceuticals INC. | $42.40 | 2024-2025 | |
| Emd Serono, INC. | $41.56 | 2024 | |
| Genmab U.S., INC. | $41.52 | 2024-2025 | Epkinly |
| Blueprint Medicines Corporation | $38.49 | 2024-2025 | Ayvakit |
| Glaxosmithkline, LLC. | $30.05 | 2024-2025 | Jemperli, Zejula |
| Invivyd INC | $25.79 | 2025 | Pemgarda |
| Agios Pharmaceuticals, INC. | $22.07 | 2025 | Pyrukynd |
| Pharmaand Gmbh | $21.83 | 2025 | Rubraca |
| Janssen Pharmaceuticals, INC | $20.51 | 2025 | |
| Mirati Therapeutics, INC. | $18.55 | 2024 | Krazati |
| Geron Corporation | $14.82 | 2025 | Rytelo |
| Tolmar, INC. | $14.26 | 2025 | Rubraca |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruno Bastos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.